Our study provides valuable information from the real world about neoadjuvant anti-HER2 treatment in early breast cancer, showing that the rate of pCR obtained by double blockade with pertuzumab plus trastuzumab exceeds by 20% that obtained with trastuzumab alone. Here, ERBB2 is linked to breast carcinoma.